Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Opus Genetics, Inc. IRD

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$14.2M
▲ 29.1% YoY
$-49.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 14.2M
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 14.2 · Net income -49.6
15.0M30.0M-25.0M-50.0M
2007201020132016201920222025
Compound annual growth
−29.1%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−349 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -271.9% · Net -349.3%
-1000%-2000%-3000%
200720162025
ROE
FY2025 · ROE -449.4%
20%40%-200%-400%
200720162025
Three returns, three denominators.

Each USD of equity lost 449 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2020 · FCF -6.8
-2.5M-5.0M
200720162025
Net buybacks $ Dividends $
FY2011 · Dividends · · Net buybacks -59240.0
-50000-100000
200920102011

Total assetsUSD 50.2M
EquityUSD 15.3M
CashUSD 45.1M
Gross debtUSD 1.1M
Net debtUSD -44.0M
Current ratio6.43×

The company holds more cash than debt.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IRD, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.0◌◌◌◌◌0.00.00.00.00.0◌◌
Operating income $B−0.0−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌
EBITDA $B−0.0−0.1−0.00.0−0.0−0.0−0.0◌◌◌◌−0.0−0.0−0.0−0.0◌◌◌◌
Income tax $B0.00.00.00.00.00.00.0◌◌◌◌◌0.00.00.00.00.0◌◌
Net income $B−0.0−0.1−0.00.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌−0.0−0.0◌◌◌◌◌◌◌◌◌◌◌◌
EPS, diluted $−0.80−2.15−0.460.87−3.82−5.28−2.17−5.25−0.92−0.43−0.79−0.11−0.07−0.06−0.12−0.18−0.05◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−449.4−203.2−20.852.3————−149.6−51.9−63.4−94.5−85.7−61.5−107.5−183.3——−463.6
Shares out B0.070.030.020.020.020.010.000.040.030.240.200.180.150.120.100.08◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image